Results 21 to 30 of about 115,857 (253)

Myeloproliferative neoplasms [PDF]

Clinical Medicine, 2013
The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire   +3 more sources

Morphology of myeloproliferative neoplasms

International Journal of Laboratory Hematology, 2023
AbstractMyeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia‐negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre‐fibrotic myelofibrosis and primary myelofibrosis (PMF).
Zi Yun Ng, Kathryn A. Fuller, Allegra Mazza‐Parton, Wendy N. Erber   +3 more
openaire   +2 more sources

Genomics of Myeloproliferative Neoplasms [PDF]

Journal of Clinical Oncology, 2017
Myeloproliferative neoplasms (MPNs) are a group of related clonal hematologic disorders characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute myeloid leukemia. Deregulated JAK2 signaling has emerged as the central phenotypic driver of BCR -ABL1–negative MPNs and a unifying therapeutic target. In
Zoi, Katerina, Cross, Nicholas
openaire   +2 more sources

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2

Biomarker Research, 2021
Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined ...
Simone Romagnoli, Niccolò Bartalucci, Francesca Gesullo, Manjola Balliu, Stefania Bonifacio, Anair Graciela Lema Fernandez, Francesco Mannelli, Davide Bolognini, Elisabetta Pelo, Cristina Mecucci, Paola Guglielmelli, Alessandro Maria Vannucchi   +11 more
doaj   +1 more source

Epigenetics in myeloproliferative neoplasms

Frontiers in Oncology, 2023
The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis. Epigenetic changes are the reversible modifications to DNA- and RNA-associated proteins that impact gene activity without changing the DNA sequence ...
Greenfield, Graeme, McMullin, Mary Frances   +1 more
openaire   +4 more sources

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Blood Cancer Journal, 2021
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality.
Paola Guglielmelli, Giuseppe G. Loscocco, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Patrizia Chiusolo, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro M. Vannucchi   +15 more
doaj   +1 more source

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. [PDF]

, 2021
Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematological disorders presenting with an increased proliferation in one or several hematological cell lines. Renal manifestations of MPN have not been fully characterized so far.
Person, Fermin, Menter, Thomas, Meyer, Sara C., Hopfer, Helmut   +3 more
core   +2 more sources

Genetics of Myeloproliferative Neoplasms [PDF]

The Cancer Journal, 2014
In the last decade, genomic studies have identified multiple recurrent somatic mutations in myeloproliferative neoplasms (MPNs). Beginning with the discovery of the JAK2 V617F mutation, multiple additional mutations have been found that constitutively activate cell-signaling pathways, including MPL, CBL, and LNK.
Aaron D, Viny, Ross L, Levine
openaire   +2 more sources

Update in the myeloproliferative neoplasms [PDF]

Clinical Medicine, 2014
The differential diagnosis of haematological abnormalities, such as leucocytosis, erythocytosis, thrombocytosis or indeed anaemia, is wide and disarming. Here we report on significant updates in the differential diagnosis of erythrocyosis and thrombocytosis presenting a simplified schema for the clinician.
Harrison, Claire N, McMullin, Mary F
openaire   +3 more sources

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms [PDF]

, 2021
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often
Acha, Pamela, Sole, F., Universitat Autònoma de Barcelona, Palomo Sanchís, Laura   +3 more
core   +3 more sources